Advanced Accelerator Applications
20 Rue Diesel
Saint Genis Pouilly
78 articles with Advanced Accelerator Applications
Days after Novartis axed one-fifth of its research programs, the Swiss pharma giant said it intends to seek regulatory approval for 60 new treatments between 2019 and 2021.
Shares of Indiana-based Endocyte have shot up more than 50 percent in pre-market trading after Swiss pharma giant Novartis announced it was acquiring the company for $2.1 billion in cash. The deal will allow the company to expand its radiopharmaceuticals business.
Pharma and biotech companies across the globe continued to expand and reshape their leadership teams with new hires this past week. BioSpace collected several announced leadership appointments, which includes new chief executive officers, new members to boards of directors and more.
Advanced Accelerator Applications Signs Exclusive License Agreement With Cancer Targeted Technology to Develop CTT1057, an F-18 Labeled PSMA Ligand for Diagnostic Applications in Prostate Cancer
The terms of the agreement include an upfront licensing fee, as well as certain milestone and royalty payments.
Novartis Completes Subsequent Offering Period of the Tender Offer for Advanced Accelerator Applications S.A.
The subsequent offering period for the Offer, which commenced on January 22, 2018, expired as scheduled at 12:00 midnight, New York City Time, on January 31, 2018.
The drug is the first available FDA-approved Peptide Receptor Radionuclide Therapy.
Novartis Completes Tender Offer for Advanced Accelerator Applications S.A. and Announces Commencement of Subsequent Offering Period
The deal expands Novartis Oncology neuroendocrine tumor treatment portfolio and adds radiopharmaceutical technology platform.
From 1997 through 2013, there was an average of 27 novel drugs approved in the U.S. per year.
The Offer will expire at 12:00 midnight, New York City time, on January 19, 2018, unless extended (the latest time and date at which the Offer will expire, the “Expiration Date”).
Advanced Accelerator Applications Board of Directors Recommends $3.9B All Cash Tender Offer by Novartis
The transaction is subject to customary transactional regulatory approvals.
Sales for the third quarter of 2017 increased 39% compared to the third quarter of 2016
Advanced Accelerator Applications Announces European Approval Of Lutetium (177Lu) Oxodotreotide (Lutathera) For Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors
Advanced Accelerator Applications And FUJIFILM RI Pharma Announce First Patient In Bridging Study In Japan For Lutetium Lu 177 Dotatate* (Lutathera)
Advanced Accelerator Applications Announces New Prescription Drug User Fee Act (PDUFA) Date Of January 26, 2018, For Lutetium Lu 177 Dotatate (Lutathera)
Advanced Accelerator Applications Completes Resubmission Of NDA For Lutetium Lu 177 Dotatate (Lutathera) To FDA
EU Regulators Give Nod to Advanced Accelerator Applications ' Med to Treat the Cancer That Killed Steve Jobs
Advanced Accelerator Applications And Blue Earth Diagnostics Announce European Manufacturing And Distribution Agreements For Axumin (Fluciclovine (18F)) For PET Imaging Of Recurrent Prostate Cancer